Industry reports
Editor highlights

Publication dates

data types

Celgene Market and Forecasts, April 2014

You might be interested in: ovarian cancer, drug, insulin, more »


 

» View Public Reports

1-10 of 43 reports for Celgene

U.S. Drug and Medication Business Brief

  • Industry report
  • February 2012
  • 19 pages
  • by Corporation

... Patients (aged 65 Years) filed claims for mds in 2003 * * source: cyclacel est. &Amp; golberg, s, et al, jco, 2010. Revlimid , celgene. # Vidaza , celgene. &Amp; dacogen , eisai. Dacogen and vidaza ...

Drug and Medication Sector in The United States

  • Industry report
  • October 2012
  • 22 pages
  • by Corporation

... Revlimid , celgene. Vidaza , celgene. &Amp; dacogen , eisai. Dacogen and vidaza are hypomethylating(hm) agents. Nccn guidelinesmds v.2.2011P. 19. Prebett, gore s, et al,jco 2011; jabbour ...

Pharmaceutical in Austria and Germany : Innovation and Technology Trends

  • Industry report
  • March 2013
  • 33 pages

... Conference seventh alpine meeting, march 25-27, austria the views expressed in this presentation are the speakers , Not necessarily celgene S. Remaining years of life at indicated age (austria 2009) 0 5 ...

Medicine Sector in Canada

  • Industry report
  • January 2012
  • 10 pages
  • by Governmental Agency

... Is to make a payment in the amount of $10,000,000 to the government of canada no later than february 20, 2012, in order to comply with the guidelines. celgene will also ensure that the average transaction ...

World Nanomedicine Industry Brief

  • Industry report
  • January 2014
  • 9 pages

... Include ge healthcare, merck & co inc., Abbott laboratories, pfizer inc., Nanosphere inc., Mallinckrodt plc, teva pharmaceutical industries ltd., Sigma-tau pharmaceuticals inc., celgene corporation ...

Pharmaceutical Business in The United States and Canada

  • Industry report
  • June 2012
  • 22 pages

... Biosciences Abcam Agilent technologies Amgen Biogen idec Bristol-myers squibb Cephalon celgene corporation Cellectis Cerus Covance biomarker center of excellence Cyprotex ...

Drug Market in Canada

  • Industry report
  • March 2012
  • 17 pages
  • by Governmental Agency

... The board has the authority to regulate prices of Patented generics Issue before the federal court of canada celgene corporation, and the patented medicine thalomid Jurisdictional issue: does ...

U.S. Pharmaceutical Industry : Innovation and Technology Trends

  • Industry report
  • February 2013
  • 25 pages

... Of completion of the last therapy. The drug was approved under the agency S accelerated approval program. Pomalidomide is an analogue of thalidomide (thalomid celgene) and carries similar risks to this drug ...

Pharmaceutical Key Market Figures in The United States

  • Industry report
  • March 2012
  • 27 pages

... Date. Percentage of total value is calculated compared to total value for the relevant year $350m celgene acquisition of avila does not include upto $575m in additional milestones 2010 acquiror ...

The Future of Biological Therapy

  • Industry report
  • April 2012
  • 20 pages

... Opsanitx reference deals -$400m+ upfront total glaxosmithkline and amplimmune $23m $508m sanofi-aventis and oxford biomedica $39m $690m celgene ...

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.